Overview Technical Risk & rank Quality Results Accounts Filings Options Guidance & governance
Guidance tracker
What GLENMARK guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 05 Nov 2026 | Glenmark Pharmaceuticals filed its Q2 FY27 investor presentation (dated 05 November 2026) under Regulation 30 of the SEBI Listing Obligations rules. Q2 FY27 consolidated revenue was Rs 42,473 million, down 29.8% YoY from Rs 60,469 million but up 5.7% QoQ; like-for-like YoY growth was about 20%. Q2 FY27 EBITDA was... NSE copy | No results filed since | ||
| 11 Sep 2026 | Glenmark Pharmaceuticals filed under Regulation 30 a rating rationale from India Ratings and Research dated September 10, 2026. India Ratings upgraded GPL's long-term bank loans to 'IND AA+'/Stable from 'IND AA' and affirmed short-term bank loans at 'IND A1+'. Rated bank loan facilities of INR18,500 million... NSE copy | -56.8 % | -31.3 % | +4.4 % |
| 09 Jun 2026 | Glenmark Pharmaceuticals filed the presentation for its Investor Day 2026, held on June 9, 2026 in Mumbai. Management stated the company has about US$2bn consolidated revenue (FY26, converted at ₹88.33 per US$), about 17,000 employees, 11 manufacturing sites, and operations in more than 80 countries. Management... NSE copy | +930.3 % | +23.1 % | -0.2 % |
| 30 Jan 2026 | Glenmark Pharmaceuticals filed its Q3 FY26 investor presentation dated 30 January 2026 under Regulation 30 of the SEBI LODR Regulations. Q3 FY26 consolidated revenue was Rs. 39,006 Mn, up 15.1% YoY; EBITDA was Rs. 8,697 Mn (22.3% margin); PAT was Rs. 4,032 Mn (10.3% margin), including an exceptional item of Rs.... NSE copy | - | - | -3.2 % |
| 14 Nov 2025 | Glenmark Pharmaceuticals filed its Q2 FY26 investor presentation (dated November 14, 2025) under Regulation 30. Consolidated revenue for Q2 FY26 was Rs 60,469 Mn, up 76.1% YoY, with EBITDA of Rs 23,596 Mn (39.0% margin) and PAT of Rs 6,104 Mn (10.1% margin). The presentation covers the AbbVie partnership for ISB... NSE copy | +15.9 % | +15.1 % | -3.8 % |
| 19 Sep 2025 | CRISIL Ratings revised the outlook on Glenmark Pharmaceuticals' long-term bank facilities to 'Positive' from 'Stable' and reaffirmed the long-term rating at 'Crisil AA'; short-term rating reaffirmed at 'Crisil A1+' (rating rationale dated September 18, 2025). Total bank loan facilities rated: Rs.1850 crore. The... NSE copy | +72.2 % | +76.1 % | -1.4 % |
| 14 Aug 2025 | Glenmark Pharmaceuticals filed its Q1 FY26 investor presentation dated August 14, 2025. Consolidated revenue was Rs. 32,644 Mn, up 0.6% YoY; US (North America) business grew 8.9% QoQ and India business grew 3.7% YoY. EBITDA was Rs. 5,805 Mn with a 17.8% margin; Adjusted PAT was Rs. 3,129 Mn (9.6% margin), adjusted... NSE copy | +72.2 % | +76.1 % | -1.4 % |
| 16 Jul 2025 | Glenmark Pharmaceuticals filed the investor presentation for its Investor Day 2025, held in Mumbai on July 16, 2025. The presentation describes the company as having about US$1.6 billion consolidated revenue (FY25), 11 manufacturing sites, 15,000+ employees, presence in over 80 countries, and more than 60% of... NSE copy | -86.2 % | +0.6 % | -3.5 % |
| 14 Feb 2025 | Glenmark Pharmaceuticals filed its Q3 FY25 investor presentation dated February 14, 2025 under Regulation 30 of the SEBI LODR Regulations. Consolidated revenue for Q3 FY25 was Rs. 33,876 Mn, up 35.1% YoY; EBITDA was Rs. 6,002 Mn (17.7% margin); PAT was Rs. 3,480 Mn (10.3% margin). India business revenue was Rs.... NSE copy | -86.2 % | +0.6 % | -3.5 % |
Filings tagged as guidance, newest first (9 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 11 Sep 2026 | Credit rating | Glenmark Pharmaceuticals filed under Regulation 30 a rating rationale from India Ratings and Research dated September 10, 2026. India Ratings upgraded GPL's long-term bank loans to 'IND AA+'/Stable from 'IND AA' and affirmed short-term bank loans at 'IND A1+'. Rated bank loan facilities of INR18,500 million... NSE copy |
| 31 Jul 2026 | Management change | Board of Glenmark Pharmaceuticals approved unaudited standalone and consolidated results for the quarter ended June 30, 2026, and the related limited review report. Standalone net sales for the quarter were Rs 23,425.26 million and standalone profit after tax was Rs 7,356.37 million; consolidated net sales were Rs... NSE copy |
| 29 May 2026 | Legal or regulatory | Glenmark Pharmaceuticals filed its Q4 FY26 investor presentation (dated 29 May 2026) under Regulation 30 of the SEBI LODR Regulations. Q4 FY26 consolidated revenue was Rs. 37,706 million, up 15.8% YoY; EBITDA was Rs. 7,626 million (margin 20.2%); PAT was Rs. 3,013 million (PAT margin 7.6%). Full-year FY26... NSE copy |
| 29 May 2026 | Management change | Glenmark Pharmaceuticals' board, at its meeting held May 29, 2026, noted the early retirement of Mr. Harish Kuber as Company Secretary & Compliance Officer, effective close of business hours of May 29, 2026. The board approved the appointment of Ms. Rashmi Khandelwal (ACS 28839) as Company Secretary & Compliance... NSE copy |
| 30 Jan 2026 | Legal or regulatory | Glenmark Pharmaceuticals filed its Q3 FY26 investor presentation dated 30 January 2026 under Regulation 30 of the SEBI LODR Regulations. Q3 FY26 consolidated revenue was Rs. 39,006 Mn, up 15.1% YoY; EBITDA was Rs. 8,697 Mn (22.3% margin); PAT was Rs. 4,032 Mn (10.3% margin), including an exceptional item of Rs.... NSE copy |
| 30 Jan 2026 | Legal or regulatory | Glenmark Pharmaceuticals' board approved unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025 at a meeting held on 30 January 2026 (meeting 4:30 pm to 6:40 pm). Consolidated net sales for Q3 FY26 (quarter ended 31/12/2025) were Rs 38,879.99 million, against... NSE copy |
| 14 Nov 2025 | Legal or regulatory | Glenmark Pharmaceuticals filed its Q2 FY26 investor presentation (dated November 14, 2025) under Regulation 30. Consolidated revenue for Q2 FY26 was Rs 60,469 Mn, up 76.1% YoY, with EBITDA of Rs 23,596 Mn (39.0% margin) and PAT of Rs 6,104 Mn (10.1% margin). The presentation covers the AbbVie partnership for ISB... NSE copy |
| 14 Nov 2025 | Management change | Glenmark Pharmaceuticals approved unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2025 at a board meeting held on 14 November 2025. Standalone Q2 FY26 (quarter ended 30/09/2025): total revenue from operations Rs 15,386.60 million; loss after tax Rs (7,391.89)... NSE copy |
| 26 Sep 2025 | Management change | Glenmark Pharmaceuticals' board on 26 September 2025 approved an interim dividend of ₹2.50 per equity share (face value ₹1) for FY 2025-26, amounting to ₹705.50 million. The record date for the interim dividend is Friday, 3 October 2025, as intimated earlier on 22 September 2025; the dividend will be paid within 30... NSE copy |
| 19 Sep 2025 | Credit rating | CRISIL Ratings revised the outlook on Glenmark Pharmaceuticals' long-term bank facilities to 'Positive' from 'Stable' and reaffirmed the long-term rating at 'Crisil AA'; short-term rating reaffirmed at 'Crisil A1+' (rating rationale dated September 18, 2025). Total bank loan facilities rated: Rs.1850 crore. The... NSE copy |
| 14 Aug 2025 | Legal or regulatory | Glenmark Pharmaceuticals filed its Q1 FY26 investor presentation dated August 14, 2025. Consolidated revenue was Rs. 32,644 Mn, up 0.6% YoY; US (North America) business grew 8.9% QoQ and India business grew 3.7% YoY. EBITDA was Rs. 5,805 Mn with a 17.8% margin; Adjusted PAT was Rs. 3,129 Mn (9.6% margin), adjusted... NSE copy |
| 14 Aug 2025 | Legal or regulatory, Management change | Glenmark Pharmaceuticals filed the outcome of its board meeting held on August 14, 2025. The board approved transfer of the Consumer Care business to its newly incorporated wholly owned subsidiary Glenmark Consumer Care Limited; the business had FY2025 turnover of INR 514.7 Crs (5.6% of standalone turnover) and the... NSE copy |
| 14 Aug 2025 | Legal or regulatory | Glenmark Pharmaceuticals filed its unaudited standalone and consolidated financial results for the quarter ended 30 June 2025, approved by the Board on 14 August 2025 (meeting 2:00 p.m. to 4:11 p.m.). Standalone Q1 FY26 total income was Rs 24,642.63 million and profit after tax was Rs 3,296.92 million, against Rs... NSE copy |
| 23 Jul 2025 | Credit rating | Glenmark Pharmaceuticals filed an India Ratings and Research rating rationale dated July 23, 2025 under Regulation 30 of the SEBI LODR Regulations. India Ratings revised the Outlook on Glenmark's long-term bank facilities to Positive from Stable and affirmed the rating at 'IND AA'; short-term non-fund-based limits... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (14 in all). A list of what was filed, not a judgement of the company.